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Abstract 
Background: The objectives of the study were to estimate the incidence of intensive care unit (ICU) admissions due 
to adverse drug events (ADEs), to assess preventability, severity and costs of the corresponding ADE and to determine 
the leading causes of preventable ADEs.
Methods: An observational study was conducted in a medical ICU of a teaching hospital from February 2013 to 
February 2014.
Results: A total of 743 consecutive admissions were included, and they involved 701 different patients. The included 
admissions were categorized into three groups (admissions due to preventable ADE, admissions due to unprevent‑
able ADE and the control group). Among the 743 ICU admissions included during the study period, 173 (23.3 %) were 
due to ADE, with 102 (13.7 %) related to preventable ADE and 71 (9.6 %) to unpreventable ADE, yielding a preventabil‑
ity rate of ADE of 0.59 (102/173). Admissions due to unpreventable ADE concerned patients with more comorbidities, 
a greater number of drugs and higher Simplified Acute Physiology Score II than admissions due to preventable ADE 
and the control group admissions (n = 570). Hospital mortality rates, corresponding costs and length of stay were all 
similar in the preventable ADE and control groups, whereas they were always significantly higher in the unprevent‑
able ADE group. ICU mortality, length of stay and the corresponding costs were similar in the three groups. Non‑com‑
pliance was the principal leading cause of preventable ADE (n = 31/102). The 102 preventable ADE‑related admis‑
sions accounted for a total of 528 days of hospitalization in the ICU, requiring a mean of 1.4 ICU beds per day over the 
one‑year period, with an associated total cost amounting to 747,651 €.
Conclusions: ADE was a major cause of admission in the studied ICU, and in 59 % of the cases, ADEs were prevent‑
able. The reported burden of ICU admissions due to ADE advocates for further investigations to explore how the rate 
of such admissions could be decreased.
Keywords: Drug‑related side effects and adverse reactions, Medication errors, Medication adherence, Self‑
medication, Intensive care units, Incidence
© 2016 Jolivot et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Drug-related problems are a significant burden for 
healthcare facilities as they account for 5.3–12.1  % of 
hospital admissions, depending on the studies and the 
definition used for an adverse drug event [1, 2]. For 
instance, adverse drug events (ADEs) were defined by 
Nebeker et al. [3] as “any injury from medical interven-
tion related to a drug.” This broad definition encompasses 
unpreventable ADEs also called adverse drug reactions 
(ADRs) and preventable ADEs, resulting from medica-
tion errors (ME).
An ADR was defined by the World Health Organiza-
tion (WHO) as “any noxious and unintended effect of 
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a drug occurring at doses normally used in man for the 
prophylaxis, diagnosis, or therapy of the disease, or for 
the modification of physical function” [4]. Finally, ME, 
as opposed to ADR, can be defined as “any preventable 
events that may cause or lead to inappropriate medica-
tion or patient harm while the medication is in the con-
trol of the healthcare professional, patient or consumer” 
[3]. Preventable events include drug overuse, underuse 
and misuse as defined by the American National Round-
table on Health Care Quality [5].
Patients hospitalized for an ADE have longer hospi-
tal length of stay (LOS) and higher risks of death than 
other patients [6]. Admissions into the intensive care unit 
(ICU) deserve special attention since they account for 
most severe admission cases with a potential fatal threat. 
However, data related to ADE as a cause of ICU admis-
sion are scarce and heterogeneous. Based on 12 studies 
published between 1986 and 2014 [7–18], a recent sys-
tematic review reported incidences of ICU admissions 
due to an ADE ranging from 0.37 to 27.4 % and mortality 
rates ranging from 2 to 28.1 % [7–19]. Preventable ADEs 
accounted for 17.5 to 85.7  % of the ICU admissions. 
Many features contributed to the studies’ heterogene-
ity, including case mix, ADE definitions, methods used 
for assessing causality and preventability. Moreover, the 
leading causes of preventable ADE were poorly inves-
tigated [7, 8, 10, 12, 13]. It is important to note that the 
implication of non-compliance or self-medication in ICU 
admissions was not explored in these studies. Finally, 
the costs of ICU admissions due to ADE and of LOS 
were seldom assessed [10, 17]. Therefore, we undertook 
a study examining in detail the critical issues related to 
the admissions to ICU related to an ADE. Based on the 
admissions observed in a medical ICU during a one-year 
period, our main objective was to determine the inci-
dence of ICU admissions due to an ADE. We also identi-
fied which admissions were related to a preventable ADE 
and determined the leading causes of the corresponding 
ADE, and which were related to an unpreventable ADE. 
Finally, the severity of patients’ condition, the LOS and 
the associated costs were compared in the three groups 
of admissions considered: preventable ADE-attributed 
admissions, unpreventable ADE-attributed admissions 
and the control group.
Methods
Study design and setting
This observational monocentric study was conducted 
over a one-year period, from February 24, 2013, to 
February 23, 2014, in a 18-bed medical ICU of a uni-
versity-affiliated 760-bed hospital (Saint-Antoine Hos-
pital, AP-HP, Paris, France). Saint-Antoine hospital 
is a multidisciplinary hospital with specialization in 
hepato-gastroenterological and onco-hematological 
diseases and a solid tumor and hematopoietic stem cell 
transplantation expertise. The hospital is also equipped 
with a digestive surgical ICU (the present study was not 
conducted in the latter unit). Patients were followed up 
from their admission in the ICU through to their dis-
charge from the hospital.
Participants
The inclusion criterion was the following: all ICU admis-
sions occurring during the study period. Exclusion crite-
ria were age under 18, patient refusal or impossibility to 
investigate the treatment or medical history and patients 
admitted and discharged during the same weekend. 
Patients admitted for external care (bronchoscopy, renal 
replacement therapy for chronic renal failure or central 
venous catheter insertion) were also excluded from the 
study. Readmissions were considered as new ICU admis-
sions and analyzed accordingly.
The need for a written consent was waived since it was 
a study on usual care, without any specific intervention. 
All patients and relatives were informed that anonymous 
data could be used for academic research. The study was 
approved by an institutional review board (Commission 
d’Ethique de la Société de Réanimation de Langue Fran-
çaise, Paris, France).
Admissions’ screening
Two investigators, a pharmacist (PAJ) and an ICU phy-
sician (CP), screened independently all ICU admissions 
during the morning staff meeting from Monday to Friday. 
After reviewing each medical chart, they independently 
sorted all included admissions into two groups: the ADE 
group (ICU admissions due to ADE) and the control 
group (ICU admissions for a matter other than ADE). In 
case of disagreement, BG (Professor of Intensive Care) or 
CF (Professor of Clinical Pharmacy) classified the admis-
sion as related or not to an ADE.
For both assessors, the causal relationship between 
drugs and clinical features was assessed according to 
chronological, semiological and bibliographical data. 
Chronological data included the chronology of the events 
(drug administration or interruption and clinical signs), 
assessment of drug exposure at the beginning of the first 
clinical signs, taking into account drug pharmacokinet-
ics. Additionally, clinical consequences (recovering or 
not) after drug dechallenge/rechallenge were assessed 
when possible. Semiological data were based on deter-
mining the possible etiologies of the observed clinical 
signs and on specific laboratory test results. Bibliographi-
cal data search was mainly based on the Summary Prod-
uct Characteristics (SmPC), and in the case of lack of 
information in the SmPC, additional sources of data were 
Page 3 of 12Jolivot et al. Ann. Intensive Care  (2016) 6:9 
used (Micromedex® and/or search in Embase database or 
MEDLINE database via PubMed).
ADEs were classified as preventable or unpreventable 
according to the Schumock and Thornton modified crite-
ria (see the subsection Data sources/measurement—pre-
ventability in the “Methods” section) [20]. Preventable 
ADEs were subcategorized into 3 classes according to the 
cause of the event: drug overuse, underuse and misuse. 
Drug overuse stood for situations in which potential for 
harm exceeded the possible benefit. Drug underuse cor-
responded to failures to detect diseases or to use proven 
effective treatments. Drug misuse corresponded to an 
appropriate treatment with occurrence of a preventable 
complication  [5]. Non-compliance and self-medication 
were considered as misuses.
ICU admissions related to non-compliance and self-
medication were included in the ADE group, whereas 
admissions related to self-poisoning were included in the 
control group.
Data sources/measurement
For all included ICU admissions
The following data, available in medical records, were 
collected for every included ICU admission: age, gender, 
comorbidities, patients’ origin (home or hospital), main 
reason for admission (according to the 10th International 
Classification of Diseases) [21] and LOS or vital sta-
tus at ICU and hospital discharge. The Simplified Acute 
Physiology Score II [22] and the Sequential Organ Fail-
ure Assessment [23] were calculated within a period of 
24  h after ICU admission. The McCabe score was used 
as an integrative index of the severity of underlying 
medical condition [24]. The need for and the number of 
organ supports were recorded (invasive or noninvasive 
mechanical ventilation, vasopressors, massive transfu-
sion or renal replacement therapy).
Patient origin was considered as home if he/she had 
been admitted into the ICU through the French Emer-
gency Medical Aid Unit or after visiting Emergency 
Department. In any other cases (i.e., transfer to the ICU 
from another unit or from another hospital), patient ori-
gin was considered as hospital.
In order to identify all drugs prescribed before admis-
sion and self-medication and to detect non-compliance, 
the patients and/or their relatives were questioned and 
medical records were analyzed. Whenever drug prescrip-
tions were unavailable, general practitioners, specialists 
or pharmacists in charge of the patients were contacted. 
Whenever patients were hospitalized before ICU admis-
sion, the list of all drugs administered during the hospi-
tal stay was retrieved. A dichotomous categorization of 
drugs was considered according to the delay between 
ICU admission and drug prescription: either at most a 
month or more.
ICU and hospital costs are expressed in euros for the 
year 2013. These were the direct costs of the hospitaliza-
tion adopting the perspective of the payer, i.e., the total 
fees of the admissions invoiced to the payer. Costs were 
directly issued from the administrative database of the 
hospital and are based on the French Diagnosis-Related 
Group system specially adapted to ICU admissions 
including the need for organ support [25].
Specifically for the ADE group
Drug classes and  clinical features For each drug sus-
pected of being involved in an ADE, the investigators 
recorded the following data: route of administration, daily 
schedule, starting time and end of treatment, and biologi-
cal parameters. Drug classes were coded according to the 
Anatomical Therapeutic and Chemical (ATC) classifica-
tion system [26].
Main ADE-related organ failures were classified 
according to the System Organ Class (SOC) codes of 
Medical Dictionary for Regulatory Activities (MedDRA) 
version no. 18.0 (Additional file 1: Table S1).
Causality Except for admissions due to non-compliance 
and lack of treatment, the relationship between a drug 
and an ADE was evaluated using 3 standardized causality 
assessment methods: the official French method [27] and 
2 international methods, the Naranjo [28] and the Karch 
and Lasagna methods [29]. ICU admissions were allocated 
to the ADE group if a drug was very likely (or certain), 
likely (or probable) and possibly involved according to at 
least 2 out of 3 causality assessment methods. Whenever 
several drugs were involved in a single ICU admission, the 
strongest causality link was retained to characterize the 
admission.
Preventability The preventability of ADE was assessed 
according to Schumock and Thornton [20] with an addi-
tive criterion (ADEs due to the lack of treatment were 
considered preventable) and a modified criterion (ADEs 
were considered preventable if the type of drug–drug 
interaction was contraindicated). Whenever several ADEs 
were involved in a single ICU admission, the admission 
was considered as unpreventable if at least one ADE was 
unpreventable.
Both above-mentioned investigators independently 
identified the leading causes of preventable ADE accord-
ing to a pre-established list. In the case of several leading 
causes for a single admission, the principal leading cause 
was retained. The cause of admission was then subclassi-
fied as related to drug underuse, overuse or misuse.
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Definitions used for ADE, ADR, ME, assessment meth-
ods for preventability and causality are presented in 
Additional file 2: Table S2.
Bias
As described above, the sorting of patients into one of the 
two groups (ADE or control) was made according to 3 
causality assessment methods. These methods are based 
on the literature data and on chronological, semiologi-
cal and pharmacological analysis. Moreover, this sorting 
was assessed by two independent investigators who both 
intended the daily ICU medical staff.
Study size
Study size was planned to obtain a reasonable con-
fidence interval of the incidence of ICU admissions 
caused by ADE. Assuming such an incidence to be at 
15 % (a rough estimate issued from a pilot experiment 
conducted in our ICU) and about 700 ICU admissions 
that would be included in the study in 1 year, the period 
of a one-year study was retained. According to Agresti 
and Coull method [30], such a study would a mean inci-
dence estimate of [95 % confidence interval] 15 % [12.5; 
17.9].
Quantitative variables
Each drug of a chemotherapeutic combination was con-
sidered individually for the determination of the num-
ber of drugs taken before ICU admission. However, for 
the determination of the number of drugs involved in the 
ADE, the generic term “antineoplastic agents” was used 
and the chemotherapeutic combination was counted 
as one drug in the case of drug-induced neutropenia or 
tumor lysis syndrome. Indeed, these ADEs were consid-
ered as a consequence of a combination rather than of a 
specific antineoplastic agent.
The number of comorbidities, organ supports and 
drugs involved in the ADEs were categorized into four 
groups (0, 1, 2 and ≥3) and were analyzed as categorical 
variables.
Hospital LOS, mortality and costs were censured at 
discharge from Saint-Antoine hospital.
Statistical methods
Statistical analyses
The incidence of ADE-related admissions was calculated 
as the ratio of the number ADE-related admissions to the 
total number of included ICU admissions.
Results on quantitative variables are presented as medi-
ans and inter-quartile ranges, and those on qualitative 
variables are presented as numbers and associated per-
centages. Group comparisons on quantitative and quali-
tative variables were performed with the Mann–Whitney 
and Wilcoxon test and the Fisher exact test, respectively. 
Since multiple comparisons involving 3 groups were per-
formed, the threshold P value of 0.0166 was considered 
for statistical significance, according to the applied Bon-
ferroni correction. Inter-rater agreement (ADE vs control 
group, 3 causality assessment methods and preventability 
assessment) was assessed with the kappa test [31]. Statis-
tical analysis was performed with R Studio software (ver-
sion 0.98.490).
Sensitivity analysis
As our study was focused on the burden of admissions 
caused by unintentional medication related problems, all 
other admissions including self-poisoning were put in the 
control group. Nevertheless, a sensitivity analysis exclud-
ing self-poisoning cases was conducted in order to (1) 
be consistent with previous studies which had excluded 
such cases [7, 11, 13, 14, 17] and (2) explore the impact of 
self-poisoning cases on the study results.
Results
There were 743 admissions included in the study out 
of the 1016 recorded ICU admissions (Fig.  1). Included 
admissions concerned 701 patients (33 patients were 
admitted twice, three patients were admitted three times, 
and one patient was admitted four times). There were 173 
and 570 admissions finally categorized as ADE-related 
and control admissions (inter-rater agreement corre-
sponding kappa test = 0.97), respectively, resulting in an 
incidence estimate of ADE-related admissions at 23.3 % 
[95  % confidence interval (CI) 20.4–26.5]. There were 
71 ICU admissions attributed to unpreventable ADE 
(41.0  % [95  % CI 34.0–48.5] of ADE-related admissions 
or 9.6  % [95  % CI 7.6–11.9] of all ICU admissions) and 
102 to preventable ADE (59.0  % [95  % CI 51.5–66.0] of 
ADE-related admissions or 13.7 % [95 % CI 11.4–16.4] of 
all ICU admissions). The corresponding inter-rater agree-
ment was excellent (kappa test = 0.98).
Table  1 details the baseline characteristics of the 
patients at admission in the ICU in the three groups con-
sidered (preventable ADE-related group, unpreventable 
ADE-related group and control group). Age and gender 
did not significantly differ from one group to another. 
The main organ failures associated with each ATC class 
are summarized in Additional file  1: Table S1. The 173 
ADE-related admissions were associated with 219 drugs 
which induced 219 organ failures (100 were in the unpre-
ventable group and 119 in the preventable group).
Unpreventable ADEs
ICU admissions attributed to unpreventable ADE 
affected patients with a significantly higher number of 
comorbidities, higher McCabe score and higher SAPS 
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II than patients of the other groups (Table  1). In addi-
tion, admissions for shock were more frequent and 
patients originated more often from another depart-
ment or another hospital. Examination of patients’ 
drug histories (Table  2) indicated that patients admit-
ted for an unpreventable ADE-related admission had 
a significantly higher number of drugs recently intro-
duced. Drugs involved in the unpreventable ADEs were 
more frequently prescribed at hospital, and nearly two-
thirds were either antineoplastic and immunomodulat-
ing agents or drugs acting on blood and blood-forming 
organs (Table  3). Hospital mortality was significantly 
increased in patients with unpreventable ADE-related 
admission. Corresponding total LOS and hospital costs 
were significantly higher (Table 4).  
Preventable ADEs
Preventable ADE-related and control groups shared a 
substantial number of patient baseline characteristics 
(Table  1). However, a significantly higher number of 
underlying diseases were observed in the preventable 
ADE-related group, and admissions for a metabolic dis-
order as well as renal replacement therapy were more 
frequent. Patients’ treatments prior to ICU admission 
included more drugs and more recently introduced drugs 
than those observed in the control group (Table 2). The 
most frequent types of drugs involved in preventable 
ADEs were cardiovascular drugs, nervous system drugs 
and drugs acting on blood and blood-forming organs 
(Table 3).
Unlike unpreventable ADE-related admissions, pre-
ventable ADE-related admissions did not significantly 
differ from control admissions in terms of hospital LOS 
and costs (Table 4). More importantly, the 102 prevent-
able ADE-related admissions accounted for a total of 
528  days of hospitalization in the ICU, equivalent to 
the requirement of 1.4 beds during the one-year study 
period. Moreover, the total costs related to these ICU 
periods of hospitalization observed during the year 
amounted to 747,651 €.
Considering the 102 ICU preventable ADE-related 
admissions, 77 were related to drug misuse, 16 to drug 
underuse and 9 to drug overuse (Fig.  2). The most fre-
quent leading cause for drug misuse was non-compliance 
(30  % of ICU admissions related to preventable ADEs). 
The chronic diseases for which patients were not com-
pliant with their medication were diabetes (n = 10), epi-
lepsy (n = 6), cardiac chronic failure (n = 5), HIV (n = 4) 
and other conditions (n  =  6). Reasons for non-compli-
ance were psychiatric illness (n = 10), misunderstanding 
(n = 10), patient’s refusal (n = 8), cognitive impairment 
(n = 2) or omission (n = 1).
Fig. 1 Flowchart of the study. ICU intensive care unit, ADE adverse drug event
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Table 1 Baseline characteristics of the patients at admission in the intensive care unit
























1.2 × 10−2 5.7 × 10−3 6.7 × 10−9
 0 95 (13 %) 5 (5 %) 0 (0 %) 90 (16 %)
 1 200 (27 %) 27 (27 %) 9 (12 %) 164 (29 %)
 2 234 (31 %) 34 (33 %) 25 (35 %) 176 (31 %)






415 (56 %) 66 (65 %) 48 (66 %) 302 (53 %) 0.87 3.1 × 10−2 4.3 × 10−2
 Chronic heart 
failure
87 (12 %) 18 (18 %) 15 (21 %) 54 (9 %) 0.56 2.2 × 10−2 6.8 × 10−3
 Chronic renal 
failure
118 (16 %) 20 (20 %) 18 (25 %) 80 (14 %) 0.46 0.17 2.1 × 10−2
 Chronic respira‑
tory disease
119 (16 %) 13 (13 %) 7 (10 %) 99 (17 %) 0.63 0.31 0.12
 Neuropsychiat‑
ric disease
181 (24 %) 30 (30 %) 13 (18 %) 138 (24 %) 0.11 0.27 0.30
 Cirrhosis 84 (11 %) 10 (10 %) 18 (25 %) 80 (14 %) 1.1 × 10−2 3.9 × 10−2 4.7 × 10−3
 Solid tumor 109 (15 %) 12 (12 %) 14 (20 %) 83 (15 %) 0.20 0.54 0.29
 Hematological 
malignancy
104 (14 %) 15 (15 %) 28 (38 %) 62 (11 %) 5.8 × 10−4 0.30 4.2 × 10−8
 Immunodefi‑
ciency
188 (25 %) 32 (31 %) 47 (66 %) 109 (19 %) 6.7 × 10−6 7.9 × 10−3 1.4 × 10−15
McCabe score 
[n (%)]
1.6 × 10−3 0.55 6.7 × 10−5
 No fatal under‑
lying disease










91 (12 %) 11 (11 %) 21 (30 %) 59 (10 %)
 SAPS II (median 
[IQR])
40[29; 54] 42 [32; 51] 47 [37; 61] 40 [28; 54] 1.3 × 10−2 0.44 7.7 × 10−4
 SOFA score 
(median 
[IQR])
5 [3; 9] 5 [3; 9] 7 [4; 10] 5 [2; 8] 1.8 × 10−2 0.19 1.4 × 10−4
Patients’ origin 
[n (%)]




400 (54 %) 59 (58 %) 26 (35 %) 316 (55 %)
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ADE adverse drug event, ED emergency department, ICU intensive care unit, IQR inter-quartile range, SAPS II Simplified Acute Physiology Score II, SOFA Sequential 
Organ Failure Assessment
Table 1 continued

















343 (46 %) 43 (42 %) 45 (65 %) 254 (45 %)
Main reason for 
admission [n 
(%)]
1.5 × 10−4 3.8 × 10−8 1.2 × 10−2
 Acute respira‑
tory failure
259 (35 %) 24 (24 %) 20 (28 %) 215 (38 %)
 Metabolic 
disorders
95 (13 %) 32 (31 %) 6 (8 %) 57 (10 %)
 Cardiac arrest 22 (3 %) 5 (5 %) 3 (4 %) 14 (2 %)
 Neurologic 
disorders
162 (22 %) 26 (25 %) 14 (19 %) 122 (21 %)
 Shock 172 (23 %) 15 (15 %) 28 (40 %) 129 (23 %)
 Other 33 (4 %) 0 (0 %) 0 (0 %) 33 (6 %)
Table 2 Drug history before intensive care unit admission
ADE adverse drug event, ICU intensive care unit, IQR inter-quartile range, NA non-applicable
a Admissions due to non-compliance or drug underuse were excluded from the analysis (44 admissions in the preventable group) in the analysis of the item “number 
of drugs involved”
b Admissions due to self-medication, compliance problems or drug underuse













Number of drugs 




5 [2; 8] 5 [3; 8] 6 [4; 9] 5 [2; 8] 0.17 0.15 4.3 × 10−3
Number of drugs 




3 [1; 5] 4 [1; 7] 8 [4; 12] 2 [0; 4] 6.0 × 10−6 1.6 × 10−4 2.2 × 10−16





9 [5; 13] 11 [7; 15] 15 [12; 20] 8 [4; 11] 8.5 × 10−7 3.1 × 10−5 2.2 × 10−16
Number of drugs 
involved in the 
ADEa [n (%)]
0.19 NA NA
 1 NA 33 (57 %) 29 (41 %) NA
 2 NA 15 (26 %) 24 (34 %) NA
 ≥3 NA 10 (17 %) 18 (25 %) NA
Origin of prescrip‑
tions, n (%)
2.2 × 10−16 NA NA
 Hospital NA 30 (29 %) 59 (83 %) NA
 Community NA 19 (19 %) 12 (17 %) NA
 Otherb NA 53 (52 %) 0 (0 %) NA
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Sensitivity analysis
Excluding from the analyses, the 26 admissions due to 
drug-related self-poisoning only resulted in the follow-
ing changes: incidence estimate (among all admissions) 
of ADE-related, unpreventable ADE-related, and pre-
ventable ADE-related admissions increased from 23.3 to 
24.1  % [95  % CI 20.4–26.5], from 9.6 to 9.9  % [95  % CI 
7.9–12.3] and from 13.7 to 14.2  % [95  % CI 11.8–17.0], 
respectively; the hospital mortality in the unprevent-
able ADE and control groups was no longer significantly 
different; the frequency of the use of renal replacement 
therapy compared in the preventable ADE and control 
groups was no longer significantly different either (see 
Additional file  3: Table S3, Additional file  4: Table S4, 
Additional file 5: Table S5).
Discussion
We have undertaken a one-year study analysis of admis-
sions into a single ICU, focusing on ADEs. We have cho-
sen a broad definition of ADE, including preventable and 
unpreventable ADE, as defined by Nebeker et al. [3] and 
the American National Roundtable on Health Care Qual-
ity [5].
We found an incidence of 23.3  % of ICU admissions 
due to ADE. Preventable ADEs accounted for 13.7  % 
and unpreventable ADEs for 9.6  % of ICU admissions. 
The incidence of ICU admissions due to ADE found in 
our study is the third highest incidence reported in the 
literature [7–18]. This high proportion of ICU admissions 
due to ADE can be explained by (1) the use of a broad 
definition of ADE, taking into account unpreventable 
ADE and all types of preventable ADE and (2) the pro-
file of the hospital in which the study was conducted 
with oncology, hematology and hepatology departments 
which can be important providers of unpreventable ADE 
(in Table  3, note the high frequency of involvement of 
antineoplastic and immunomodulating agents in unpre-
ventable ADE). Non-compliance was the leading cause of 
preventable ADEs. Importantly, the results indicate that 
preventable ADEs constitute a significant burden in ICU 
routine practice, with the requirement of 1.4 beds each 
day in the ICU, and a total corresponding direct cost of 
747,651 euros for the duration of the study.
Study limitations and strengths
Our study has some limitations. It is a monocentric study 
conducted in an ICU located in a hospital with depart-
ments specialized in oncology, hematology and hepatol-
ogy. This might explain the observed high mortality rate 
and the length of hospital stay. We did not attempt to 
assess ADE-attributed mortality since it is almost impos-
sible to assess respective contribution of underlying dis-
ease and drugs.
The study has also many strengths. To our knowledge, 
it is the first to examine in such great detail ICU admis-
sions related to an ADE. The prospective screening of 
the present study allowed very accurate data collec-
tion of patient drug history and causality/preventability 
Fig. 2 Analysis of preventable adverse drug events by main leading causes. ADE adverse drug event
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assessments. In order to minimize clinical judgment 
influence, inclusions in the ADE or in the control group 
were independently performed by a clinical pharmacist 
and an ICU physician, with a high inter-rater reliability. 
This reliability was much higher than that reported by 
others [12].
For causality assessment, 3 different scales were used 
[27–29]. As previously reported by Kane-Gill et  al. [32] 
and Jolivot et  al. [19], Karch and Lasagna and Naranjo 
scales are not tailored for ICU as ADE should be 
excluded if patient’s condition did not improve after drug 
dechallenge. Due to the severity of most of the cases, 
this condition cannot be fulfilled in ICU. Furthermore, 
rechallenge as suggested by Karch and Lasagna is unethi-
cal, since ADE was the leading cause of admission. Nev-
ertheless, applying these scales allowed some comparison 
with international studies. The third scale is better suited 
for ICU [27] but has only been used in French studies. 
Hence, in order to be comprehensive, we applied Kane-
Gill et al. recommendations [33] and used these 3 scales 
of assessment.
The sensitivity analysis indicates that considering 
admissions attributed to drug-related self-poisonings in 
the control group or excluding such admissions from the 
analyses had a very moderate impact on the study results. 
This can be explained by the small proportion of these 
admissions in the control group (n = 26) and their asso-
ciated relatively low severity.
Unpreventable ADEs
Unpreventable ADEs accounted for 41 % of ICU admis-
sions related to ADE. In this group, patients took more 
drugs before ICU admission than in the control group.
The patient case mix which involved immunocompro-
mised and onco-hematological patients might explain 
both this high proportion (with frequent events due to 
antineoplastic and immunomodulating agents and fre-
quent admissions for shock, especially septic shock) [34] 
and the higher severity score observed in the unprevent-
able ADE group. The proportion of unpreventable ADEs 
such as sepsis during febrile aplasia was particularly high, 
as previously reported by Nazer et al. [17].
Preventable ADEs
Preventable ADEs accounted for 59 % of ICU admissions 
related to ADE. Previous studies reported corresponding 
estimates within a range of 17.5–85.7 % [7–18, 35], and 
adding our study to these would rank the present study 
estimate at 4/9. Cost, LOS and mortality were similar to 
those of control group, suggesting that these preventable 
ADEs are as life-threatening as other events leading to 
ICU admission. This also suggests that implementation of 
corrective action might be cost-saving.
ICU admissions due to preventable ADEs involved 
recently introduced treatments (prescribed for less than 
a month) and mainly drugs for the cardiovascular (30 %) 
and nervous systems (25 %). Nervous system drugs were 
also one of the most frequent classes of drugs prescribed 
in France in 2013 [36]. This raises the important question 
of the relative potential of drugs to induce ADE. Further 
studies dealing with this issue should be performed.
Eight studies have focused on the determination of 
the leading causes of ICU admissions due to prevent-
able ADE [7–10, 12, 14, 17, 18]. Similar leading causes to 
that found in our study were reported (in variable pro-
portions): drug misuse (dose error, inadequate follow-up, 
drug interaction, administration error and contraindi-
cation), underuse (absence of prophylaxis) and overuse 
(inappropriate drug). However, the present study is the 
first to date to provide a comprehensive description of 
non-compliance and self-medication as leading causes 
of ICU admissions. The fact that patients in the pre-
ventable ADE group came more often from home or the 
Emergency Department than those in the unpreventable 
ADE group is in line with the study of Heaton et al. which 
reported that non-compliance substantially required 
Emergency Department visits [37]. In our study, medica-
tion non-compliance was the principal leading cause of 
Table 3 Drugs involved in preventable and unpreventable 
adverse drug events according to  the anatomical thera-
peutic and  chemical (ATC) classification (one ADE can be 
due to more than one drug)













3 (3 %) 41 (41 %) 44 (20 %)
Cardiovascular system 36 (30 %) 8 (8 %) 44 (20 %)
Blood and blood‑
forming organs
20 (17 %) 23 (23 %) 43 (20 %)
Nervous system 30 (25 %) 13 (13 %) 43 (20 %)
Systemic hormonal 
preparation (except 
sex hormones and 
insulin)
9 (8 %) 7 (7 %) 16 (7 %)
Anti‑infective for 
systemic use
7 (6 %) 5 (5 %) 12 (5 %)
Alimentary tract and 
metabolism
4 (3 %) 2 (2 %) 6 (3 %)
Musculoskeletal 
system
6 (5 %) 0 (0 %) 6 (3 %)
Others 4 (3 %) 1 (1 %) 5 (2 %)
Total 119 (100 %) 100 (100 %) 219 (100 %)
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ICU admissions due to preventable ADE (30 %), showing 
that adherence failure might also generate severe out-
comes and a significant burden for the healthcare system.
A third of the medication non-compliance-related 
admissions (n  =  10) resulted from misunderstanding 
problems from patients with chronic disease who did 
not understand that they had to take their chronic treat-
ments for life. Low patient adherence is a substantial 
problem in therapy. As shown by our study, it can lead 
to ICU admission. Causes of non-adherence are vari-
ous and include poor patient education, level of under-
standing, lack of explanations given by the doctor or 
lack of pharmacist intervention. Many interventions 
were tested to enhance therapy adherence (e.g., induc-
ing behavior change in patients, face-to-face informa-
tion delivery by pharmacists, connexion between daily 
routine and drug administration). However, the authors 
of a recent meta-analysis conclude that a number of 
clinical trials describing interventions intended to 
enhance patient adherence lack proving their efficacy [38].
Reducing the substantial burden of ICU admissions 
due to preventable ADE is an issue of concern. Future 
research should explore how various interventions might 
favorably impact this burden, such as physician train-
ing, drug conciliation by a pharmacist or therapeutic 
education.
Conclusions
In this observational study, we report that 23.3  % of 
ICU admissions were caused by an ADE, with 59  % of 
them related to a preventable ADE. Nearly a third of 
the corresponding preventable ADEs were due to non-
compliance. Our study provides a strong rationale for 
undertaking future studies to explore the impact of 
potential corrective actions aiming at reducing ADE-
related ICU admissions.
Table 4 Treatments and outcomes of intensive care unit admissions
ADE adverse drug event, ICU intensive care unit, IQR inter-quartile range

















Number of organ support(s) 
[n (%)]
0.34 0.37 0.28
 0 312 (42 %) 48 (47 %) 25 (35 %) 239 (42 %)
 1 232 (31 %) 31 (30 %) 22 (31 %) 179 (31 %)
 2 128 (17 %) 12 (12 %) 13 (18 %) 103 (18 %)
 ≥3 71 (10 %) 11 (11 %) 11 (16 %) 49 (9 %)
Type of organ support [n 
(%)]
 Noninvasive ventilation 115 (15 %) 10 (10 %) 8 (11 %) 97 (17 %) 0.80 7.7 × 10−2 0.30
 Invasive ventilation 270 (36 %) 30 (29 %) 29 (41 %) 211 (37 %) 0.14 0.15 0.52
 Catecholamine 237 (32 %) 27 (26 %) 33 (46 %) 177 (31 %) 9.1 × 10−3 0.41 0.11
 Renal replacement 
therapy
70 (9 %) 16 (16 %) 10 (14 %) 44 (8 %) 0.83 1.4 × 10−2 0.11
 Massive blood transfusion 
(>1/2 blood volume)
26 (3 %) 7 (7 %) 6 (8 %) 13 (2 %) 0.77 2.1 × 10−2 1.3 × 10−2
Mortality during ICU admis‑
sion [n (%)]a
125 (17 %) 14 (14 %) 18 (25 %) 93 (16 %) 7.2 × 10−2 0.56 6.7 × 10−2
Mortality during hospital 
admission[n (%)]a
161 (22 %) 17 (17 %) 25 (35 %) 119 (21 %) 6.7 × 10−3 0.42 9.8 × 10−3
Length of ICU stay (median 
[IQR])
4 [2; 7] 4 [2; 7] 4 [2; 9] 4 [2; 7] 0.15 0.49 0.26
Length of hospital stay 
(median [IQR])
13 [6; 29] 13 [5; 28] 23 [9; 48] 12 [5; 28] 5.4 × 10−3 0.47 1.2 × 10−4
Estimated costs (euros)of 








4694 [2 342; 10 
301]
7.4 × 10−2 0.52 0.11
Estimated costs (euros)










8.5 × 10−4 0.97 5.2 × 10−5
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